Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, et al. Histological classification of ovarian cancer. Med Electron Microsc. 2003;36:9–17.

Article  PubMed  Google Scholar 

Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773.

Article  PubMed  Google Scholar 

Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020;4:e000629.

Article  PubMed  PubMed Central  Google Scholar 

Bullock TN. Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer. Curr Opin Immunol. 2017;45:82–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu W, Maben Z, Wang C, Lindquist KC, Li M, Rayannavar V, et al. Structural delineation and phase-dependent activation of the costimulatory CD27:CD70 complex. J Biol Chem. 2021;297:101102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lens SM, Tesselaar K, van Oers MH, van Lier RA. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol. 1998;10:491–9.

Article  CAS  PubMed  Google Scholar 

Tesselaar K, Xiao Y, Arens R, van Schijndel GM, Schuurhuis DH, Mebius RE, et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol. 2003;170:33–40.

Article  CAS  PubMed  Google Scholar 

Oshikawa Y, Makino T, Nakayama M, Sawamura S, Makino K, Kajihara I, et al. Increased CD27 expression in the skins and sera of patients with systemic sclerosis. Intractable Rare Dis Res. 2020;9:99–103.

Article  PubMed  PubMed Central  Google Scholar 

Lutfi F, Wu L, Sunshine S, Cao X. Targeting the CD27-CD70 pathway to improve outcomes in both checkpoint immunotherapy and allogeneic hematopoietic cell transplantation. Front Immunol. 2021;12:715909.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563–77.

Article  PubMed  Google Scholar 

Lambin P, Zindler J, Vanneste BG, De Voorde LV, Eekers D, Compter I, et al. Decision support systems for personalized and participative radiation oncology. Adv Drug Deliv Rev. 2017;109:131–53.

Article  CAS  PubMed  Google Scholar 

Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62.

Article  PubMed  Google Scholar 

Li H, Robinson K, Lan L, Baughan N, Chan CW, Embury M et al. Temporal Machine Learning Analysis of prior mammograms for breast Cancer risk prediction. Cancers (Basel). 2023;15.

Zhang S, Shao H, Li W, Zhang H, Lin F, Zhang Q et al. Intra- and peritumoral radiomics for predicting malignant BiRADS category 4 breast lesions on contrast-enhanced spectral mammography: a multicenter study. Eur Radiol. 2023.

Yoo J, Lee J, Cheon M, Kim H, Choi YS, Pyo H et al. Radiomics Analysis of (18)F-FDG PET/CT for prognosis prediction in patients with Stage III Non-small Cell Lung Cancer undergoing Neoadjuvant Chemoradiation Therapy followed by surgery. Cancers (Basel). 2023;15.

Zhou C, Hou L, Tang X, Liu C, Meng Y, Jia H, et al. CT-based radiomics nomogram may predict who can benefit from adaptive radiotherapy in patients with local advanced-NSCLC patients. Radiother Oncol. 2023;183:109637.

Article  PubMed  Google Scholar 

Avesani G, Tran HE, Cammarata G, Botta F, Raimondi S, Russo L et al. CT-Based Radiomics and Deep learning for BRCA mutation and progression-free survival prediction in Ovarian Cancer using a Multicentric dataset. Cancers (Basel). 2022;14.

Li C, Wang H, Chen Y, Zhu C, Gao Y, Wang X, et al. Nomograms of combining MRI multisequences Radiomics and clinical factors for differentiating high-Grade from Low-Grade Serous Ovarian Carcinoma. Front Oncol. 2022;12:816982.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rizzo S, Manganaro L, Dolciami M, Gasparri ML, Papadia A, Del Grande F. Computed Tomography based Radiomics as a predictor of Survival in Ovarian Cancer patients: a systematic review. Cancers (Basel). 2021;13.

Vivian J, Rao AA, Nothaft FA, Ketchum C, Armstrong J, Novak A, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35:314–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, et al. European Society of Gynaecological Oncology (ESGO) guidelines for ovarian Cancer surgery. Int J Gynecol Cancer. 2017;27:1534–42.

Article  PubMed  Google Scholar 

Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;2011:CD007565.

PubMed  PubMed Central  Google Scholar 

Swiderska J, Kozlowski M, Gaur M, Pius-Sadowska E, Kwiatkowski S, Machalinski B et al. Clinical significance of BTLA, CD27, CD70, CD28 and CD80 as diagnostic and prognostic markers in Ovarian Cancer. Diagnostics (Basel). 2022;12.

Wouters MC, Komdeur FL, Workel HH, Klip HG, Plat A, Kooi NM, et al. Treatment regimen, Surgical Outcome, and T-cell differentiation influence Prognostic Benefit of Tumor-infiltrating lymphocytes in high-Grade Serous Ovarian Cancer. Clin Cancer Res. 2016;22:714–24.

Article  CAS  PubMed  Google Scholar 

Guo Y, Yang N, Li G, Yin X, Dong L. Identification of an Immune Gene-based cisplatin response model and CD27 as a therapeutic target against Cisplatin Resistance for Ovarian Cancer. J Immunol Res. 2022;2022:4379216.

Article  PubMed  PubMed Central  Google Scholar 

Shiomi M, Matsuzaki S, Serada S, Matsuo K, Mizuta-Odani C, Jitsumori M, et al. CD70 antibody-drug conjugate: a potential novel therapeutic agent for ovarian cancer. Cancer Sci. 2021;112:3655–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanborn RE, Pishvaian MJ, Callahan MK, Weise A, Sikic BI, Rahma O et al. Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. J Immunother Cancer. 2022;10.

Zhang H, Mao Y, Chen X, Wu G, Liu X, Zhang P, et al. Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study. Eur Radiol. 2019;29:3358–71.

Article  PubMed  Google Scholar 

Qian L, Ren J, Liu A, Gao Y, Hao F, Zhao L, et al. MR imaging of epithelial ovarian cancer: a combined model to predict histologic subtypes. Eur Radiol. 2020;30:5815–25.

Article  CAS  PubMed  Google Scholar 

Jian J, Li Y, Pickhardt PJ, Xia W, He Z, Zhang R, et al. MR image-based radiomics to differentiate type iota and type IotaIota epithelial ovarian cancers. Eur Radiol. 2021;31:403–10.

Article  PubMed  Google Scholar 

Yao F, Ding J, Lin F, Xu X, Jiang Q, Zhang L, et al. Nomogram based on ultrasound radiomics score and clinical variables for predicting histologic subtypes of epithelial ovarian cancer. Br J Radiol. 2022;95:20211332.

Article  PubMed  PubMed Central  Google Scholar 

Song XL, Ren JL, Yao TY, Zhao D, Niu J. Radiomics based on multisequence magnetic resonance imaging for the preoperative prediction of peritoneal metastasis in ovarian cancer. Eur Radiol. 2021;31:8438–46.

Article  PubMed  Google Scholar 

Yu XY, Ren J, Jia Y, Wu H, Niu G, Liu A, et al. Multiparameter MRI Radiomics Model predicts preoperative peritoneal carcinomatosis in Ovarian Cancer. Front Oncol. 2021;11:765652.

Article  PubMed  PubMed Central  Google Scholar 

Chen HZ, Wang XR, Zhao FM, Chen XJ, Li XS, Ning G, et al. The Development and Validation of a CT-Based Radiomics Nomogram to Preoperatively Predict Lymph Node Metastasis in High-Grade Serous Ovarian Cancer. Front Oncol. 2021;11:711648.

Article  PubMed  PubMed Central  Google Scholar 

Li HM, Gong J, Li RM, Xiao ZB, Qiang JW, Peng WJ, et al. Development of MRI-Based Radiomics Model to predict the risk of recurrence in patients with Advanced High-Grade Serous Ovarian Carcinoma. AJR Am J Roentgenol. 2021;217:664–75.

Article  PubMed  Google Scholar 

Wang X, Xu C, Grzegorzek M, Sun H. Habitat radiomics analysis of pet/ct imaging in high-grade serous ovarian cancer: application to Ki-67 status and progression-free survival. Front Physiol. 2022;13:948767.

Article  PubMed  PubMed Central